Advertisement
Sleep Apnea

First Daily Pill From the GLP-1 Family Significantly Reduces Sleep Apnea Severity in Two Phase 3 Trials

Eli Lilly's orforglipron, taken once a day as a pill rather than injected, nearly quadrupled the reduction in breathing interruptions seen with placebo in the ATTAIN-OSA trials

ATTAIN-OSA tested a once-daily oral GLP-1 pill in adults with obstructive sleep apnea and excess weight

Eli Lilly's experimental pill orforglipron (brand name Foundayo) significantly reduced the severity of obstructive sleep apnea in two Phase 3 clinical trials, according to results presented November 9 at the American Heart Association Scientific Sessions 2026 and simultaneously published in JAMA.

The findings mark the first large trials of an oral medication in the GLP-1 drug class — the same family as semaglutide and tirzepatide, which are typically injected — specifically for obstructive sleep apnea (OSA).

What the Trials Found

The two 52-week, randomized, double-blind, placebo-controlled trials, together called ATTAIN-OSA, enrolled 712 adults with moderate to severe obstructive sleep apnea who also had obesity or were overweight. One trial included participants not using positive airway pressure (PAP) therapy; the other included participants who were already on PAP.

At 52 weeks, the apnea-hypopnea index (AHI) — the standard measure of how many breathing interruptions occur per hour of sleep — fell by a mean of 17.8 events per hour in the orforglipron group versus 4.5 with placebo in the first trial, and by 17.3 versus 5.3 in the second (p < 0.001 in both). In percentage terms, Lilly reported an average AHI reduction of 43.8% among participants not using PAP and 27.5% among those who continued using PAP alongside the drug.

More than 40% of treated participants in the non-PAP trial achieved at least a 50% reduction in their AHI. Hypoxic burden — a measure of how much and how often oxygen levels drop during sleep — improved by an average of 55.9% without PAP and 45.8% with PAP, and markers of inflammation (hsCRP) also improved more than with placebo.

Why an Oral GLP-1 Matters

GLP-1 medications have already shown they can ease sleep apnea by driving weight loss, which reduces fat deposits around the airway that contribute to nighttime collapse. Both tirzepatide and the injectable triple-hormone drug retatrutide have posted strong results in sleep apnea trials over the past year.

Orforglipron's distinction is that it is a small-molecule pill rather than an injection. That could make GLP-1 therapy accessible to patients who are needle-averse, who have difficulty with injection logistics, or who live in regions where cold-chain storage for injectable drugs is impractical. Presenting author Vaishnavi Kundel of Mount Sinai noted that these are among the first large trials to test an oral medication in this class for obstructive sleep apnea specifically, rather than for diabetes or weight loss alone.

Benefits Extended to Patients Already on CPAP

Notably, the AHI and hypoxic-burden improvements held up even among participants who remained on PAP therapy throughout the trial. That suggests orforglipron could serve as an add-on for patients whose apnea is only partially controlled by CPAP, rather than purely as an alternative to it.

One secondary measure did not reach statistical significance: there was no significant difference between orforglipron and placebo in self-reported sleep-related impairment scores at 52 weeks, even though weight loss and breathing measures improved. Researchers noted that participants' overall weight loss likely contributed to the airway improvements, consistent with how other GLP-1 drugs are thought to work in OSA.

What This Means for Patients

For the many adults with obstructive sleep apnea who also carry excess weight, orforglipron adds to a rapidly growing menu of pharmaceutical options that could someday be used alongside, or in place of, mechanical therapies like CPAP. But it is not yet approved for this use, and patients currently on CPAP or oral appliance therapy should not stop their prescribed treatment based on these results.

The companion data on patients who stayed on PAP is particularly relevant for people who tolerate their CPAP machine but still have residual breathing events or excess weight — a group for whom few add-on options currently exist. As with other weight-loss-driven apnea treatments, questions remain about what happens to breathing severity if patients stop taking the drug and regain weight, as well as long-term safety over periods longer than one year. Lilly has indicated it plans to pursue regulatory filings based on this data, meaning an approval decision specifically for the sleep apnea indication could still be a year or more away.

Advertisement